课题基金 / 基金详情

Cell decision underlying B-cell immune responses

Cell decision underlying B-cell immune responses
B 细胞免疫反应的细胞决策
批准号:
10330546
负责人:
Alexander Hoffmann
金额:
$41.9万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
未结题
起止时间:
2018-02-01 至 2025-01-31

项目摘要

项目成果

Alexander Hoffmann的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结/文摘
英文摘要
Project Summary/Abstract A hallmark of the humoral immune response is a two phased antibody response, the first being rapid and providing for low affinity antibodies, and the second occurring with a week delay but providing high affinity antibodies. An appropriate balance of both phases of the response is critical for an effective immune response. The two phased humoral immune response is governed by B-cell population dynamics that represent the composite of the decisions made by individual cells whether to enter a growth phase and the cell cycle that results in division, whether to survive or die, and whether to differentiate into antibody secreting plasma cells and/or memory B-cells. At any given timepoint there is a great variety of B-cell fates, and prior studies assumed that this is due to stochastic fate decisions by individual cells at each generation. Instead, our recently established long-term microscopy workflow revealed that cells make highly deterministic fate decisions, and that the cell-to-cell variability within the population is largely due to heterogeneity in the founder cells. This renders humoral immunity substantially more predictable, so long as we have a mechanistic understanding of how molecular networks control B-cell decision making in proliferation and differentiation. The overarching goal of the proposed project is to develop quantitative understanding and multi-scale model of how the multi-dimeric NFκB system controls B-cell decision making to effect cell survival, proliferation, and differentiation. The overarching hypothesis of the proposed studies is that the coordinated dynamics of NFκB family members RelA and cRel control the phasing of B-cell proliferation and differentiation and thus the affinity, abundance and diversity of antibodies and hence efficacy of the humoral immune response. We will address this hypothesis with an iterative systems biology approach structured into following three Specific Aims: 1. Delineate how NFκB system dynamics control the lineages of proliferating B-cells 2. Delineate how NFκB system dynamics control plasma B-cell differentiation 3. NFκB system control of humoral immunity in vivo: phasing low and high affinity antibody responses Each Aim involves novel multiscale mathematical modeling and quantitative experimentation, including unprecedented long term microscopy, novel fluorescent reporter mouse strains, and single cell genomic technologies.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
A Regulatory Circuit Controlling the Dynamics of NFκB cRel Transitions B Cells from Proliferation to Plasma Cell Differentiation.
控制 NFκB cRel 动力学的调节电路将 B 细胞从增殖转变为浆细胞分化。
DOI: 10.1016/j.immuni.2019.02.004
发表时间: 2019
期刊: Immunity
影响因子: 32.4
作者: [Roy,Koushik, Mitchell,Simon, Liu,Yi, Ohta,Sho, Lin,Yu-Sheng, Metzig,MarieOliver, Nutt,StephenL, Hoffmann,Alexander]
通讯作者: Hoffmann,Alexander
Substrate complex competition is a regulatory motif that allows NFκB RelA to license but not amplify NFκB RelB.
底物复合物竞争是一种监管主题,允许 NFκB RelA 许可但不能放大 NFκB RelB。
DOI: 10.1073/pnas.1816000116
发表时间: 2019
期刊: Proceedings of the National Academy of Sciences of the United States of America
影响因子: 11.1
作者: [Mitchell,Simon, Hoffmann,Alexander]
通讯作者: Hoffmann,Alexander
DOI: 10.3389/fimmu.2022.898078
发表时间: 2022
期刊: FRONTIERS IN IMMUNOLOGY
影响因子: 7.3
作者: [Vaidehi Narayanan, Haripriya, Hoffmann, Alexander]
通讯作者: Hoffmann, Alexander
DOI: 10.3390/biomedicines10050974
发表时间: 2022-04-22
期刊: Biomedicines
影响因子: 4.7
作者: []
通讯作者:
共 6 条
    Characterizing functional states of macrophages via their stimulus-responses
    Bruins in Genomics: Dental, Oral & Craniofacial Research Training Program (BIG DOC)
    Bruins in Genomics: Dental, Oral & Craniofacial Research Training Program (BIG DOC)
    The NFkB System in Dendritic Cells
    海外基金